Small-cell lung cancer (SCLC) has defied the scientific community for decades. Chemotherapy has been the mainstay treatment for patients with SCLC and, unlike its non-small-cell counterpart, no significant therapeutic breakthroughs have been made since the 1970s. Recently, new immunotherapeutic and targeted therapy options became available for these patients. In this article, the results obtained with these therapeutic strategies are briefly discussed.